Zacks Investment Research cut shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a hold rating to a sell rating in a research report released on Wednesday morning.
According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
A number of other equities analysts also recently weighed in on ENTA. BidaskClub raised shares of Enanta Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, November 20th. TheStreet downgraded shares of Enanta Pharmaceuticals from a b- rating to a c+ rating in a research note on Monday, November 26th. Oppenheimer set a $100.00 price target on shares of Enanta Pharmaceuticals and gave the stock a hold rating in a research note on Tuesday, November 27th. Finally, ValuEngine downgraded shares of Enanta Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Thursday, November 8th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company’s stock. Enanta Pharmaceuticals currently has an average rating of Hold and a consensus target price of $100.00.
Shares of ENTA traded down $0.14 on Wednesday, hitting $74.63. 64,796 shares of the stock traded hands, compared to its average volume of 251,574. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of 21.45 and a beta of 0.91. Enanta Pharmaceuticals has a 1 year low of $48.57 and a 1 year high of $127.77.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, November 26th. The biotechnology company reported $1.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.06. The business had revenue of $67.20 million for the quarter, compared to the consensus estimate of $69.03 million. Enanta Pharmaceuticals had a net margin of 34.82% and a return on equity of 21.56%. The company’s quarterly revenue was down 11.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.86 earnings per share. As a group, equities research analysts expect that Enanta Pharmaceuticals will post 1.7 earnings per share for the current fiscal year.
In other Enanta Pharmaceuticals news, VP Nathalie Adda sold 4,155 shares of the business’s stock in a transaction dated Thursday, September 20th. The shares were sold at an average price of $95.32, for a total transaction of $396,054.60. Following the sale, the vice president now directly owns 4,155 shares in the company, valued at approximately $396,054.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Tim Ocain sold 25,000 shares of the business’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $83.64, for a total transaction of $2,091,000.00. The disclosure for this sale can be found here. Company insiders own 10.56% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in ENTA. Vanguard Group Inc. raised its position in shares of Enanta Pharmaceuticals by 30.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,426,791 shares of the biotechnology company’s stock worth $121,934,000 after buying an additional 330,374 shares in the last quarter. Matarin Capital Management LLC bought a new stake in Enanta Pharmaceuticals during the third quarter valued at about $17,964,000. BlackRock Inc. lifted its holdings in Enanta Pharmaceuticals by 6.5% during the third quarter. BlackRock Inc. now owns 2,590,166 shares of the biotechnology company’s stock worth $221,354,000 after buying an additional 157,166 shares during the period. First Manhattan Co. lifted its holdings in Enanta Pharmaceuticals by 22.7% during the third quarter. First Manhattan Co. now owns 698,434 shares of the biotechnology company’s stock worth $59,688,000 after buying an additional 129,026 shares during the period. Finally, Teachers Advisors LLC lifted its holdings in Enanta Pharmaceuticals by 249.0% during the third quarter. Teachers Advisors LLC now owns 107,124 shares of the biotechnology company’s stock worth $9,155,000 after buying an additional 76,426 shares during the period. Institutional investors own 84.96% of the company’s stock.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Recommended Story: Inflation
Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.